What antipsychotic agent is approved to treat bipolar depression and approved to be utilized as an augmenting agent to SSRIS/SNRIs in unipolar depression?

A. Haloperidol: Haloperidol is a first-generation antipsychotic primarily used to treat schizophrenia and acute psychosis. It is effective for controlling positive symptoms but lacks efficacy in treating depressive symptoms associated with bipolar or unipolar depression. B. Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of bipolar depression and as an adjunct therapy for major depressive disorder. Its combined antagonism at serotonin 5HT2 and dopamine D2 receptors, along with partial agonist effects at 5HT1A receptors, contributes to its mood-stabilizing and antidepressant properties. C. Chlorpromazine: Chlorpromazine is an older antipsychotic effective for psychosis and agitation but not indicated for bipolar or unipolar depression. Its strong sedative and anticholinergic effects limit its use in depressive conditions. D. Thiothixene: Thiothixene is a typical antipsychotic mainly used for schizophrenia management. It does not possess the serotonergic or mood-stabilizing actions required for efficacy in bipolar depression or as augmentation for unipolar depressive disorders.